<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>UNLABELLED: We evaluated the efficacy and safety of the combination of twice-daily fludarabine and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (BIDFA) in patients with refractory/relapsed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> in myeloid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BP) </plain></SENT>
<SENT sid="1" pm="."><plain>One hundred seven patients were enrolled </plain></SENT>
<SENT sid="2" pm="."><plain>Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery (CRp) of 5% </plain></SENT>
<SENT sid="3" pm="."><plain>The overall 4-week mortality rate was 9% </plain></SENT>
<SENT sid="4" pm="."><plain>In conclusion, BIDFA is active and safe in heavily pretreated patients with <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>BACKGROUND: The purpose of this study was to evaluate the efficacy and safety of the combination of twice-daily fludarabine and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (BIDFA) in patients with refractory/relapsed <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), high-risk <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> in myeloid <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e> (<z:mp ids='MP_0005481'>CML</z:mp>-BP) </plain></SENT>
<SENT sid="6" pm="."><plain>PATIENTS AND METHODS: One hundred seven patients with refractory/relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, intermediate and high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, and <z:mp ids='MP_0005481'>CML</z:mp>-BP, with a performance status of 3 or less and <z:mpath ids='MPATH_458'>normal</z:mpath> organ function were treated </plain></SENT>
<SENT sid="7" pm="."><plain>Patients received fludarabine 15 mg/m(2) intravenously (IV) every 12 hours on days 1 to 5 and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 0.5 g/m(2) IV over 2 hours every 12 hours on days 1 to 5 </plain></SENT>
<SENT sid="8" pm="."><plain>Gemtuzumab ozogamicin (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GO</z:e>) was administered at 3 mg/m(2) IV on day 1 in the first 59 patients </plain></SENT>
<SENT sid="9" pm="."><plain>Patients with <z:mp ids='MP_0005481'>CML</z:mp>-BP were allowed to receive concomitant <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>RESULTS: Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery of 5% </plain></SENT>
<SENT sid="11" pm="."><plain>The overall 4-week mortality rate was 9% </plain></SENT>
<SENT sid="12" pm="."><plain>The CR rates for patients with relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with first CR duration greater than or equal to 12 months, relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with first CR duration less than 12 months, and refractory/relapsed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> beyond first salvage were 56%, 26%, and 11%, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>With a median follow-up of 7 months, the 6-month event-free survival, overall survival, and complete remission CR duration rates were 18%, 35%, and 70%, respectively </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: BIDFA is active with an overall response rate of 26% in a heavily pretreated population </plain></SENT>
<SENT sid="15" pm="."><plain>This combination is safe with a low 4-week mortality rate of 9% </plain></SENT>
</text></document>